Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
mRNA product DS release specific testing is a core quality attribute service for mRNA vaccines and therapeutics. It systematically characterizes capping efficiency, LNP encapsulation efficiency, dsRNA impurity residuals, and polyA tail length distribution, with methods designed to align with FDA and EMA requirements for mRNA drug safety and efficacy.
Creative Biogene provides one‑stop services from mRNA DS release testing to IND/BLA submission data packages, aligned with the FDA mRNA vaccine guidance framework, the EMA 2025 draft guideline on quality aspects of mRNA vaccines, and ICH Q6B.
The 5' cap structure is essential for mRNA biological function. Natural eukaryotic mRNA has an m⁷GpppN cap (Cap 0), which can be further methylated to Cap 1 (2'‑O‑methylation of the first nucleotide). The cap structure enables translation initiation via eIF4E recognition, protects mRNA from 5'→3' exonuclease degradation, and Cap 1 helps distinguish self from non‑self RNA, reducing innate immune activation.
LC‑MS/MS method (RNase H approach): RNase H specifically cleaves the 5' region of mRNA, releasing the 5' fragment for LC‑MS/MS analysis. This method clearly distinguishes Cap 0, Cap 1, Cap 2, and other cap variants and provides precise quantitation of capping efficiency.
Encapsulation efficiency is the percentage of total mRNA successfully encapsulated within lipid nanoparticles (LNPs). LNPs protect mRNA from degradation and deliver it into cells. Low encapsulation efficiency leads to rapid degradation of free mRNA, reduced delivery efficiency and protein expression, and potential non‑specific immune responses. High encapsulation efficiency is a core quality attribute for mRNA vaccines and therapeutic potency.
Method 1: RiboGreen Fluorescence Assay
RiboGreen selectively binds RNA, with fluorescence enhancement >1000‑fold. In intact LNPs, encapsulated mRNA is protected by the lipid barrier and cannot contact the dye. When a surfactant (e.g., Triton X‑100, Tween 20) disrupts LNPs, mRNA is released and binds RiboGreen, generating fluorescence. Encapsulation efficiency is calculated by comparing fluorescence before and after disruption.
Method 2: Dynamic Light Scattering (DLS)
DLS measures Brownian motion via intensity fluctuations of laser light through LNP suspension, calculating hydrodynamic diameter and polydispersity index (PDI). A narrow size distribution (PDI < 0.2) indicates LNP formulation consistency and indirectly reflects encapsulation quality.
Method 3: Cryo‑Transmission Electron Microscopy (cryo‑TEM)
Directly images LNPs in their frozen native state, observing morphology (spherical, ellipsoidal), lamellar structure, and internal electron density. Visual inspection of mRNA loading (electron density differences in LNP core) provides direct visual confirmation of encapsulation efficiency.
dsRNA is a key process‑related impurity generated during in vitro transcription (IVT), formed by RNA‑dependent RNA polymerase activity or RNA secondary structures. dsRNA impurities trigger innate immune responses via pattern recognition receptors such as TLR3, causing inflammation, and must be tightly controlled. The EMA draft explicitly requires characterization and control of process‑related impurities including dsRNA.
J2 Antibody ELISA Method: A sandwich ELISA using the J2 monoclonal antibody, which specifically recognizes double‑stranded RNA (≥40 bp) regardless of nucleotide composition or sequence. This method sensitively and selectively detects dsRNA impurities generated during IVT. The K2 and J2 antibodies were designed by Schonborn et al. for broad detection of dsRNA sequences.
The polyA tail is a homopolymer sequence of adenosine residues at the 3' end of mRNA, a critical structural feature for mRNA integrity and stability. The polyA tail binds polyA binding protein (PABP), protecting mRNA from 3'→5' exonuclease degradation, and interacts with the 5' cap binding protein eIF4G to form a closed loop promoting translation initiation. Longer polyA tails are generally associated with higher translation efficiency and longer mRNA half‑life.
Method 1: LC‑MS
RNase T1 specifically cleaves RNA (the polyA tail contains no guanosine residues, thus remains intact). PolyA tail fragments are selectively enriched using oligo(dT) magnetic beads and analyzed by high‑resolution mass spectrometry. PolyA tail length distribution is precisely determined by mass‑to‑charge ratio.
Method 2: Capillary Gel Electrophoresis (CGE)
PolyA tails are released from mRNA using RNase T1 and separated by size using CGE. This CGE method has demonstrated resolution comparable to LC‑MS, achieving single‑nucleotide resolution.
Method 3: High‑Throughput Sequencing (TAIL‑seq / Nano3P‑seq)
Sequencing methods such as TAIL‑seq and Nano3P‑seq analyze polyA tail length distribution at the transcriptome‑wide level and detect non‑adenosine residue incorporation. Nano3P‑seq is a nanopore‑based cDNA sequencing method that simultaneously quantifies RNA abundance, polyA tail length, and tail composition at the single‑molecule level.
| Document | Key Requirement |
| EMA Draft Guideline on Quality Aspects of mRNA Vaccines (2025) | Defines mRNA as the active substance; linear DNA template as starting material; release specifications should be scientifically justified per ICH Q6B during clinical development. |
| FDA CMC Framework for Gene Therapy Products | Characterization and specifications for mRNA therapies (often classified as gene therapy products in clinical trials). |
| ICH Q6B | Framework for specification setting for biotechnological products; release specifications should be scientifically justified. |
| ICH Q5A(R2) | Incorporates NGS and PCR as acceptable methods for virus detection. |
| USP (draft) | RiboGreen assay recommended for mRNA concentration and encapsulation efficiency in LNP formulations. |
| NIST | RGTM 10202 FLuc mRNA – reference material to support mRNA therapeutic development. |
For a customized DS release testing strategy, method validation, or IND/BLA submission support for your mRNA product, contact Creative Biogene’s technical team.
Q1: Are all four tests mandatory for mRNA product DS release?
A: Yes. The EMA 2025 draft explicitly requires characterization and control of capping efficiency, dsRNA impurities, and polyA tail distribution. Encapsulation efficiency is a core potency attribute for LNP‑formulated products. Non‑LNP mRNA products may have different requirements.
Q2: Why must capping efficiency be ≥95%?
A: The ≥95% industry standard is based on functional and safety considerations. Uncapped mRNA (with ppp or pRNA 5' ends) cannot be recognized by eIF4E, resulting in very low translation activity. Additionally, uncapped 5' triphosphate structures are potent agonists of RIG‑I and other pattern recognition receptors, triggering innate immune responses. For most therapeutic mRNA applications, capping efficiency below 90% likely means significant loss of functional activity and safety risks.
Q3: Why use J2 antibody instead of qPCR or NGS for dsRNA residual detection?
A: qPCR requires specific templates, but dsRNA is a heterogeneous mixture of different sequences and lengths – qPCR is not applicable. NGS has low throughput and requires complex data analysis; more importantly, NGS cannot distinguish double‑stranded RNA from single‑stranded RNA. The J2 antibody ELISA is the industry standard method for dsRNA detection – it sensitively and selectively detects dsRNA molecules (≥40 bp) regardless of nucleotide composition or sequence.
Copyright © 2026 Creative Biogene. All rights reserved.